Boehringer Ingelheim International Gmbh

Sepracor, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Sunovion Pharmaceuticals Inc.

Apsinterm LLC

Sepacor Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Chris Hugh Senanayake

Xudong Wei

Nizar Haddad

Nathan K Yee

Gerald J Tanoury

Dhileepkumar Krishnamurthy

Rogelio Perez Frutos

Paul T Grover

Zhi-Hui Lu

Zhengxu Han

Roger P Bakale

Donald W Kessler

Sonia Rodriguez

Nitinchandra D Patel

Bo Qu

Yongda Zhang

Mark G Currie

Suresh R Kapadia

Carl Alan Busacca

Stephen Alan Wald

Qun Kevin Fang

Xiao-Jun Wang

Zhulin Tan

Q Kevin Fang

Thomas Gabriel Tampone

Jinghua Xu

Jason Alan Mulder

Guisheng Li

Steve Jones

Li Feng Zhang

Jinhua Jeff Song

Fabrice Gallou

Yaping Hong

Patrick Koch

Jon Charles Lorenz

Wenjun Tang

Derek Pflum

Jianxiu Liu

John R McCullough

Peter Nickolaus

Soojin Kim

Harold Scott Wilkinson

Ulrike Werthmann

Richard F Rossi

Frank Roschangar

Bing-Shiou Yang

Daniel Robert Fandrick

Jorge L Lopez

Anjan Saha

Jean-Nicolas Desrosiers

Francis X McConville

Ming Shen

Ahmad Khodabocus

Charles P Vandenbossche

Joshua Daniel Sieber

Thomas P Jerussi

Yun Gao

Martin P Redmon

Donald L Heefner

Jonathan Timothy Reeves

Azad Hossain

Robert Hett

Pascale A J Pouzet

Kevin Q Fang

Alex Roger Jurgens

James Wallace Hilborn

Scott Harold Wilkinson

Heewon Lee

Diana Reeves

Hanxun Wei

Frank Himmelsbach

Matthias Eckhardt

Paul D Rubin

Richard John Varsolona

Thomas Nicola

Lana Louise Smith Keenan

Kostas Saranteas

Laurence John Nummy

Thomas Wirth

Wenjie Li

Jutta Kroeber

Yibo Xu

Tingjian Xiang

Jolaine Savoie

Xiufeng Sun

Pascale Arielle Jane-Josee Pouzet

Hari P R Mangunuru

Andrei A Zlota

Soumik Biswas

Isabelle Gallou

Kendricks Lao

Fran A Mcconville

Hari PR Mangunuru

Diane Crimhilda Reeves

Piperidino-dihydrothienopyrimidine sulfoxides of formula I wherein:

Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma

This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. The invention also relates to processes for preparing the novel ligands.

Chiral dihydrobenzooxaphosphole ligands and synthesis thereof

Chiral dihydrobenzoazaphosphole ligands and synthesis thereof

The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms andwherein R is Cl andwherein R may be located either in the para-, meta- or ortho-position of Ring A,wherein S* is a sulphur atom that represents a chiral center,and all pharmaceutically acceptable salts, enantiomers and racemates, hydrates and solvates thereof and the use of these compounds for the treatment of inflammatory or allergic diseases of the respiratory tract such as COPD or asthma.

Phosphine ligands of the formula Ia, IB and mixtures thereof. 

Monophosphorus ligands and their use in cross-coupling reactions

Disclosed is a process for making diastereomeric N-sulfinyl &#x3b1;-amino amides by reaction of chiral sulfinimines with formamides and lithium diisopropylamide. The process of the invention provides the N-sulfinyl &#x3b1;-amino amides in high yields and with high diastereoselectivity.

[object Object]

Disclosed are novel ruthenium compounds of formula (Ia) and (Ib): wherein Rand the moietyare defined herein. Also disclosed is a process for using these novel ruthenium compounds as catalysts for asymmetric hydrogenation and transfer hydrogenation of ketones with high reactivities and excellent selectivities.

Ruthenium catalysts and their use for asymmetric reduction of ketones

Disclosed are a process and catalysts useful for carrying out asymmetric methlyallylations. The catalysts used in the invention have the formula (IV): wherein X, X, Rand Rare as defined herein. Compounds made by the process of the invention can be used to prepare pharmaceutically active compounds such as 11-&#x3b2;-hydroxysteroid hydrogenase type 1 (11-&#x3b2;-HSD1) inhibitors including 1,3-disubstituted oxazinan-2-ones. 

Process for asymetric methylallylation in the presence of a 2,2'-substituted 1,1&#x2032;-BI-2-naphthol catalyst

The invention relates to a series of novel chiral nitrogen-phosphorus ligands of formulae (Ia) and (Ib): wherein R-Rand X are as defined herein. The invention also relates to chiral metal complexes prepared with these chiral nitrogen-phosphorus ligands. The chiral metal complexes are useful as catalysts for carrying out asymmetric hydrogenation.

Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes

Disclosed is a process for making diastereomeric compound of the formula (I): wherein m, n and Rto Rare as defined herein. The process of the invention provides the compound of formula (I) in high yield and substantially free of the corresponding diastereomers. The compounds of formula (I) prepared by the process of the invention are useful for making pharmaceutically active compounds such as 11-&#x3b2;-hydroxysteroid hydrogenase type 1 (11-&#x3b2;-HSD1) inhibitors.

Methods of making diastereomeric organic compounds

Disclosed are methods for making chiral phosphorus ligands including chiral phosphines, chiral phosphine oxides, phosphonamides, and aminophosphines. The chiral phosphorus ligands prepared by the methods of the invention are useful as components of chiral catalysts, e.g., transition metal complexes.

Process for making novel chiral phosphorus ligands

Compositions containing &#x3b2;adrenergic agonists in combination with carbonates and carbamates of the formula. and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.

The invention relates to improved methods of preparing dihydrothienopyrimidines of formula 1, and intermediates thereof, (I) wherein X is SO or SO, preferably SO, and wherein R, R, R, R, Rand Rhave the meanings given in the description. The methods according to this invention are more suitable for large-scale synthesis of said compounds than prior methods because the new synthetic process avoids distillation and chromatographic purification between steps and results in a higher overall yield of the desired product. 

Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein

Growing community of inventors

Brookfield, CT, United States of America

Chris Hugh Senanayake